Table 2.
Multivariable competing risk analysis of cancer-specific mortality.
| Cancer Specific Mortality | |||
|---|---|---|---|
| Pathological Parameter | HR | 95% CI | p |
| Preoperative PSA (ng/mL) | 0.99 | 0.95–1.02 | 0.4 |
| Age (year) | 1.1 | 1.03–1.14 | 0.001 |
| Pathological stage | |||
| pT2 | Referent | ||
| pT3a | 1.02 | 0.43–2.41 | 0.9 |
| pT3b-4 | 3.1 | 1.28–7.49 | 0.01 |
| Pathological ISUP GG | |||
| GG 1 | Referent | ||
| GG 2 | 1.9 | 0.58–6.02 | 0.3 |
| GG 3 | 4.7 | 1.18–18.47 | 0.03 |
| GG 4 | 6.8 | 1.87–24.76 | 0.004 |
| GG 5 | 20.3 | 5.55–74.31 | <0.0001 |
| SM status | |||
| Negative | Referent | ||
| Positive | 2.3 | 1.16–4.64 | 0.02 |
| Unknown | 2.2 | 0.47–9.91 | 0.3 |
| LN status | |||
| Negative | Referent | ||
| Positive | 3.2 | 1.47–6.88 | 0.003 |
| Unknown | 0.8 | 0.38–1.59 | 0.5 |
HR—hazard ratio, CI—confidence interval, PSA—prostate specific antigen, ISUP GG—International Society of Urological Pathology Grade Group, SM—surgical margins, LN—lymph nodes.